Articles tagged with Pancreatic Tumors
A study published in Nature reveals that cancer stem cells' miscommunication with their environment can trigger a self-perpetuating series of events leading to malignancy. Leptin signaling plays a surprising role in this process, which could be blocked to prevent tumor progression.
Researchers at VCU Massey Cancer Center discovered the inactivation of NF1 as a potential genetic driver for pancreatic cancer. The study suggests that targeting NF1 could create vulnerabilities for therapeutic advantage in mutant KRAS-bearing tumors.
Researchers analyzed genetic data from 233 patients with ovarian cancer and found that precise localization of BRCA gene mutations is crucial for effective treatment. The study suggests that PARP inhibitors can be highly effective in patients with mutations in the DNA-binding domain, leading to improved overall survival rates.
Researchers at University of Pittsburgh have designed novel nanoparticles that co-deliver a chemotherapy drug and a novel immunotherapy, shrinking tumors in mouse models of colon and pancreatic cancer. The therapy silences a gene involved in immunosuppression by blocking Xkr8 protein distribution on the cell membrane.
Researchers at IRB Barcelona found that senescent cells stimulate the immune system to attack tumors more effectively than dead cells. Vaccinating healthy mice with senescent cells reduced tumor growth and improved immune response in animal models of melanoma and pancreatic cancer.
Advanced nanoparticles carrying a bacterially derived compound target the STING pathway, disrupting blood vessels and stimulating an immune response. This approach suppresses tumor growth and metastasis in several types of cancers.
Researchers have found a drug that targets the key, cancer-causing gene MYC has been able to inhibit its function safely and effectively. Eight out of 12 patients showed stabilisation of disease after treatment with OMO-103, with one patient experiencing a reduction in tumour-derived DNA circulating in the blood stream.
Virginia Tech researchers found that a common oral bacterium, Fusobacterium nucleatum, drives pancreatic cancer cell proliferation and migration. The bacterium can infect normal pancreatic tissue cells, stimulating nearby cancer cells to grow and spread rapidly.
Researchers propose an optical imaging system for real-time hypoxia imaging in cancer treatment. The technique utilizes protoporphyrin IX to enhance contrast between tumors and healthy tissues, allowing for more effective surgical removal.
Researchers from Rutgers Cancer Institute have identified specific microorganisms associated with inflammation and poor survival in pancreatic tumors. These microbial signatures can be used as new targets for earlier diagnosis or treatment of the fourth leading cause of cancer death.
A new study found that the organization of different types of immune cells within pancreatic tumors is associated with patient outcomes. Immune cells called IL-10+ myelomonocytes tend to be located close to specific T cell types, which may affect cancer treatment responses.
A new genetic test called PancreaSeq accurately classifies pancreatic cysts as potentially cancerous or benign, improving the accuracy of diagnoses compared to current guidelines. The test distinguishes between different types of cysts with higher accuracy than traditional forms of surveillance and current pancreatic cyst guidelines.
A new AI tool has been developed to detect pancreatic cancer on CT scans with high accuracy, achieving 90% sensitivity and 96% specificity. The tool's performance is comparable to that of radiologists, offering a promising supplement for early detection and improved treatment outcomes.
In a Phase I/II trial, selpercatinib demonstrated a 44% objective response rate across multiple tumor types, including pancreatic and colorectal cancers. The study found responses regardless of cancer type or prior treatment history, confirming RET fusions as a tissue-agnostic target.
Researchers at Mayo Clinic Comprehensive Cancer Center found that metabolic imaging, combined with traditional treatment response assessment methods, can provide critical information to guide therapy for pancreatic cancer patients. The use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant pr...
The University of Cincinnati is conducting a study on a potential new treatment for pancreatic cancer using SapC-DOPG, a nanotechnology drug delivery system. The treatment has shown promise in reducing tumor growth by 50-80% in animal models and aims to develop an effective immunotherapy treatment.
A study found that cold temperatures activate brown adipose tissue that competes with tumors for glucose, inhibiting tumor growth and prolonging survival. Researchers suggest that cold therapy could be a promising approach to cancer therapy.
Researchers discovered cancer cells produce a unique collagen that alters the tumor microbiome and promotes cancer progression. Loss of this collagen reduces cancer cell proliferation and boosts anti-tumor immune response, offering a potential therapeutic strategy.
Researchers at Cold Spring Harbor Laboratory have developed a rapid organoid screening test that can predict response to neoadjuvant chemotherapy in pancreatic cancer patients. This test may help optimize personalized treatment plans and improve patient outcomes.
A preclinical study by Cedars-Sinai Cancer and Johns Hopkins University has discovered a novel three-step treatment that disrupts the pancreatic tumor microenvironment in laboratory mice. The treatment, which combines anti-PD-1 immunotherapy antibody, FAKi, and CXCR4, prevents cancer metastasis and bolsters the immune system.
A proteomic study of 2,002 tumors identified 11 distinct molecular subtypes across 14 tissue-based cancer types, including breast, lung, and brain cancers. These subtypes provide new insights into the deregulated pathways and processes in tumors that make them cancerous.
A drug targeting IDH1 mutations in select cancers also inhibits wild-type form under certain conditions, making it a promising therapeutic option. Laboratory experiments and mouse models demonstrate the efficacy of Ivosidenib against various cancer types, including pancreatic, colorectal, ovarian, and lung cancer.
Researchers from China have developed a novel bioconjugate that can suppress the growth of K-Ras mutant pancreatic tumors. The conjugate, which targets folate receptors and macropinocytosis, was found to be highly cytotoxic and effective at suppressing tumor growth.
A randomized study of temozolomide or temozolomide and capecitabine found the combination to be effective in treating advanced pancreatic neuroendocrine tumors, with a median overall survival of 53.8 months. Patients with MGMT deficiency showed greater odds of response.
Researchers found that exercise increased levels of adrenalin, reprogramming the immune system to recognize and attack cancer cells. This led to a 50% reduction in cancer formation and 25% decrease in tumor weight in mouse models. In human patients, exercising before surgery also improved overall survival rates.
Adding diffusion-weighted MRI to conventional MRI enhances the differentiation of locally recurrent tumor and post-surgical fibrosis in pancreatic ductal adenocarcinoma resection. The study found higher sensitivity with DWI, facilitating earlier detection of recurrences.
A new study indicates that artificial intelligence can accurately predict who will develop pancreatic cancer based on pre-diagnostic CT scan images. The AI tool was trained to analyze textural differences in the pancreas and achieved an accuracy rate of 86% in identifying those who would eventually develop the disease.
Researchers at the University of Oklahoma are testing a novel therapy that combines local laser ablation and immunostimulants to treat metastatic pancreatic cancer. The treatment aims to stimulate the immune system to fight cancer cells, with promising preliminary results in pre-clinical studies and clinical trials.
The Lustgarten Foundation has awarded Career Development Grants to Pingping Hou and Edwin Manuel to fund research on pancreas cancer. Their projects focus on immune cell populations and nutrient uptake by cancer cells, aiming to develop novel therapies.
Researchers found that pancreatic cancer cells trigger the breakdown of collagen proteins, which increases arginine levels and signals stellate cells to build fibrotic meshes around tumors. This process, known as desmoplasia, creates a dense environment that promotes aggressive growth and blocks access to therapies.
Researchers have discovered two distinct classes of cancer-associated fibroblasts that accumulate in the pancreatic tumor microenvironment and play opposing roles. The study suggests that targeting these unique cell populations may improve treatment outcomes for pancreatic cancer patients.
Researchers discovered that cancer cells use a combination of proteins to repel T cells and protect themselves from the immune system. By disabling this protection, scientists were able to allow T cells to infiltrate and attack pancreatic tumors, leading to shrinkage or disappearance.
A recent study published in Developmental Cell reveals that Kras mutation causes chromatin rearrangement, leading to stem-like cell regeneration and tumor onset. The team discovered a protein complex called AP-1 as the mediator of this process, which can be targeted with small-molecule drugs.
Researchers at the University of Illinois Chicago have developed a compound that may offer hope for pancreatic cancer treatment. The experimental compound, XP-524, has been shown to more than double the average survival time for mice with pancreatic cancer when combined with immunotherapy.
Scientists at Technical University of Munich discovered a promising combination therapy for mesenchymal PDAC subtype, showing improved T-cell infiltration and cell cycle arrest when using nintedanib with trametinib. The treatment significantly improves the response of highly aggressive mesenchymal PDAC subtypes in mice.
Researchers have designed a nanoparticle system that can deliver fluorescent dyes to diagnose and treat pancreatic cancer tumors. The system overcomes the challenge of reaching cells deep within dense tumor masses, enabling detailed images of tumor structures and potentially targeted therapies.
Researchers found that hyaluronic acid is not only present in pancreatic tumors but also serves as a nutrient source for cancer cells. This discovery indicates potential new treatments for pancreatic cancer by targeting the sugar scavenging pathway.
Researchers identified three prototypical RNA-expression states in pancreatic cancer cells and found that altering the tumor microenvironment can drive tumor cells to become more susceptible to certain drugs. This discovery opens up new possibilities for personalized medicine and targeting specific drug responses.
Researchers create a porous microneedle to deliver CAR T cells into solid tumors, improving anti-tumor effects. The strategy showed enhanced tumor infiltration and amplification of CAR T cells in melanoma models.
Researchers at Karolinska Institutet found that certain bacteria from the digestive system can cause damage to pancreatic cells, increasing the risk of malignant tumours. The study suggests that antibiotics could prevent this damage, offering a potential prophylactic intervention.
A new clinical trial by Massachusetts General Hospital shows that combining low-dose radiation with nivolumab and ipilimumab improved responses in patients with resistant colorectal and pancreatic cancers. Researchers found that tumors with higher expression of viral sequences like HERV-K were more likely to respond.
Researchers discovered chemerin, a multifunctional protein, has antitumoral properties in mouse models of cancer. Bioactive chemerin overexpression inhibits neoangiogenesis, a process distinct from normal tissue vasculature. This effect may provide a therapeutic application for targeting solid tumors.
A multi-center study demonstrated improved overall survival and quality of life for inoperable pancreatic cancer patients treated with MRIdian SMART, with a median survival of 26 months. The treatment showed low rates of major adverse events and was more effective than standard radiation therapy.
MIT engineers create system to measure generation rate and survival time of CTCs in real-time, revealing variability between different tumor types. The study suggests that small cell lung tumors can shed up to 100,000 CTCs per hour, while non-small cell lung tumors and pancreatic tumors shed fewer cells.
Researchers found that antidepressants inhibit the growth of pancreatic and colon cancers in mice by blocking a mechanism used by cancer cells to evade the immune system. The findings suggest a promising approach for combining antidepressant drugs with immunotherapy to treat incurable cancers.
Researchers at Johns Hopkins Medicine have identified promising new targets for pancreatic cancer treatment and early detection, including glycosylated proteins that could be captured in the blood for diagnosis. The study also suggests new ways to improve immune response to these tumors.
Researchers at MIT developed a new way to grow pancreatic organoids using synthetic gel, allowing for study of interactions between tumors and environment. The gel can also be used to grow other types of tissue, including intestinal and endometrial tissue.
Researchers discovered that hypoxia induces regional variations in gene-expression patterns in pancreatic cancer, with specific subpopulations of cancer cells surviving under hypoxic conditions. These findings suggest a link between hypoxia and aggressive tumor behavior, highlighting the need for targeted treatments.
Researchers have discovered that depleting macrophages in tumors activates tumor-specific cytotoxic T cells, eliminating large, RT-resistant colorectal and pancreatic cancers. SIRPalpha-depletion transforms the tumor microenvironment into a potent tumoricidal niche.
Researchers found that tumors can take up significant amounts of nanoparticle albumin-bound paclitaxel and that manipulating signaling pathways involved in nutrient uptake can enhance its consumption, boosting treatment efficacy
Researchers have identified a new mechanism by which pancreatic cancer cells de-differentiate into a progenitor state, leading to the development of highly aggressive tumors. This process is associated with poorer outcomes in patients with pancreatic neuroendocrine tumors.
Researchers found that CD40 agonist treatment before surgery improved T cell attack on tumors, with 82% of treated tumors being T-cell enriched. The treatment also reduced tumor-associated fibrosis and enhanced dendritic cells' maturity. Disease-free survival was 13.8 months, with median overall survival at 23.4 months.
Researchers at Sanford Burnham Prebys found that blocking macropinocytosis in the thick tissue surrounding a pancreatic tumor slows tumor growth. The study suggests that macropinocytosis is an important driver of pancreatic cancer growth and provides a potential therapeutic target.
Researchers have developed a lower-dose radiopharmaceutical that improves treatment efficacy for neuroendocrine cancers while reducing side effects. The new medication uses reversible binding technology to extend its half-life in the blood, providing an extended therapeutic time window and improved treatment outcomes.
Researchers developed a tumor-penetrating peptide that can deliver chemotherapy drugs deep into pancreatic cancer tumors, increasing effectiveness and reducing metastasis. The therapy showed promising results in animal models, with significant increases in survival and reductions in cancer spread.
Researchers have created a powerful therapeutic platform using a modified virus to treat pancreatic cancer. The treatment, which combines the virus with other drugs, remodels the tumour microenvironment and sensitizes tumours to immunotherapy, significantly extending survival in preclinical models.
Researchers developed a method to detect pancreatic cancer by analyzing changes in albumin's structure and function. The approach showed promise in distinguishing between benign and malignant tumours, but further testing is needed.
A recent study found that recurrent glioblastoma tumors with few mutations respond best to immunotherapy, suggesting a predictive biomarker for survival. The finding could lead to new approaches to enhance the effectiveness of immunotherapies in treating this incurable disease.
A team of researchers identified a process that promotes the growth of pancreatic cancers and developed a method to disrupt it. By inhibiting adhesion molecule CDH11, they were able to reduce tumor growth, increase the effectiveness of chemotherapy, and extend mouse survival.
Researchers at Memorial Sloan Kettering Cancer Center found that tumors with high mutation burden, particularly those with BRCA2 mutations, respond better to immunotherapy. This discovery may lead to more precise treatments for patients with BRCA2 mutations.